CO5180625A1 - 1,2,4,5-TETRAHYDRO-BENZO [D] AZEPINAS - Google Patents
1,2,4,5-TETRAHYDRO-BENZO [D] AZEPINASInfo
- Publication number
- CO5180625A1 CO5180625A1 CO00058410A CO00058410A CO5180625A1 CO 5180625 A1 CO5180625 A1 CO 5180625A1 CO 00058410 A CO00058410 A CO 00058410A CO 00058410 A CO00058410 A CO 00058410A CO 5180625 A1 CO5180625 A1 CO 5180625A1
- Authority
- CO
- Colombia
- Prior art keywords
- chr
- lower alkyl
- ncf3
- cycloalkyl
- nitro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
La presente invención se refiere a derivados de 1,2,4,5-tetrahidro-benzo[d]azepin de la fórmula general <EMI FILE="00058410_1" ID="1" IMF=JPEG >En dondeR1 significa hidrógeno, alquilo inferior, oxígeno, halógeno, ó -OR, -O(C3-C6)cicloalquilo, -O(CHR)n-(C3-C6)cicloalquilo, -O(CHR)nCN, -O(CHR)nCF3, -O(CHR)(CHR)nNR2, -O(CHR) -(CHR)nOR, -O(CHR)n-alquenilo inferior, -OCF3, -OCF2-R, OCF2-alquenilo inferior, -OCHRF, -OCHF-alquenilo inferior, -OCF2CRF2, -OCF2Br, -O(CHR)nCF2Br -O(CHR)n-fenilo, en donde el grupo fenilo opcionalmente se puede substituir independientemente uno del otro por entre uno y tres grupos alquilo inferior, alcoxi inferior, halógeno, nitro o ciano, -O(CHR)(CHR)n-morfolino, -O(CHR)(CHR)n-pirrolidino, -O(CHR)(CHR)n-piperidino, -O(CHR)(CHR)n-imidazol, -O(CHR)(CHR)n-triazol, -O(CHR)n-piridino,-O(CHR)(CHR)n-Osi-alquilo inferior,-O(CHR)(CHR)nOS(O)2-alquilo inferior, -O(CH2)nCH=CF2, -O(CHR)n-2,2-dimetil-[1,3]dioxo-Iano, -O(CHR)n-CHOR-CH2OR, -O(CHR)n-CHOR-(CHR)n-CH2 OR o -SR o S(CHR)nCOOR, ó -NR2, -N(R)(CHR) (CHR)nOR, -N(R)(CHR)nCF3, -N(R)(CHR)(CHR)n-morfolino, -N(R)(CHR)(CHR)n-imidazol, -N(R)(CHR)(CHR)n-pirrolidino, -N(R)(CHR)(CHR)n-pirrolidin-2-ona, -N(R)(CHR)(CHR)n-piperidino, -N(R)(CHR)(CHR)n-triazol, -N(R)(CHR)n-piridino, n es 1- 6; R significa hidrógeno, alquilo inferior o alquenilo inferior, independientemente uno de otro, en el caso de que haya más de un grupo R;R2 significa nitro o ciano;R3 significa hidrógeno, alquilo inferior, =O, =S, -SR, -S(O)2-alquilo inferior, -(C3-C6)cicloalquilo o piperazino, substituido opcionalmente por alquilo inferior, o -CONR2, -(CHR)nCONR2, -(CHR)nOR, -(CH2)n-CF3, -CF3, -(CHR)nOC(O)CF3, -(CHR)nCOOR, -(CHR)nSC6H5, en donde grupo fenilo opcionalmente puede estar substituido independientemente uno de otro por entre uno y tres grupos alquilo inferior, alcoxi inferior, halógeno, nitro o ciano, -(CHR)n-1,3-dioxo-1,3-dihidro-isoindol,-(CHR)n-tetrahidro-piran-2-iloxi o -(CHR)n-S-alquilo inferior, o -NR2, NRCO-alquilo inferior, -NRCHO,-N(R)(CHR)nCN, -N(R)(CHR)nCF3, -N(R)(CHR)(CHR)n-OR, ...The present invention relates to 1,2,4,5-tetrahydro-benzo [d] azepin derivatives of the general formula <EMI FILE = "00058410_1" ID = "1" IMF = JPEG> Where R1 means hydrogen, lower alkyl , oxygen, halogen, or -OR, -O (C3-C6) cycloalkyl, -O (CHR) n- (C3-C6) cycloalkyl, -O (CHR) nCN, -O (CHR) nCF3, -O (CHR ) (CHR) nNR2, -O (CHR) - (CHR) nOR, -O (CHR) n-lower alkenyl, -OCF3, -OCF2-R, OCF2-lower alkenyl, -OCHRF, -OCHF-lower alkenyl, - OCF2CRF2, -OCF2Br, -O (CHR) nCF2Br -O (CHR) n-phenyl, wherein the phenyl group can optionally be substituted independently of one another by between one and three lower alkyl, lower alkoxy, halogen, nitro or cyano groups , -O (CHR) (CHR) n-morpholino, -O (CHR) (CHR) n-pyrrolidino, -O (CHR) (CHR) n-piperidino, -O (CHR) (CHR) n-imidazole, - O (CHR) (CHR) n-triazole, -O (CHR) n-pyridino, -O (CHR) (CHR) n-Osi-lower alkyl, -O (CHR) (CHR) nOS (O) 2-alkyl lower, -O (CH2) nCH = CF2, -O (CHR) n-2,2-dimethyl- [1,3] dioxo-ione, -O (CHR) n-CHOR-CH2OR, -O (CHR) n -CHOR- (CHR) n-CH2 OR or -SR or S (CHR) nCOOR, or -NR2, -N (R) (CHR) (CHR) nOR, -N (R) (CHR) nCF3, -N (R) (CHR) (CHR) n-morpholino, - N (R) (CHR) (CHR) n-imidazole, -N (R) (CHR) (CHR) n-pyrrolidino, -N (R) (CHR) (CHR) n-pyrrolidin-2-one, -N (R) (CHR) (CHR) n-piperidino, -N (R) (CHR) (CHR) n-triazole, -N (R) (CHR) n-pyridino, n is 1-6; R means hydrogen, lower alkyl or lower alkenyl, independently of one another, if there is more than one group R; R2 means nitro or cyano; R3 means hydrogen, lower alkyl, = O, = S, -SR, - S (O) 2-lower alkyl, - (C3-C6) cycloalkyl or piperazino, optionally substituted by lower alkyl, or -CONR2, - (CHR) nCONR2, - (CHR) nOR, - (CH2) n-CF3, - CF3, - (CHR) nOC (O) CF3, - (CHR) nCOOR, - (CHR) nSC6H5, wherein phenyl group may optionally be independently substituted from one another by between one and three lower alkyl, lower alkoxy, halogen groups, nitro or cyano, - (CHR) n-1,3-dioxo-1,3-dihydro-isoindole, - (CHR) n-tetrahydro-pyran-2-yloxy or - (CHR) nS-lower alkyl, or -NR2 , NRCO-lower alkyl, -NRCHO, -N (R) (CHR) nCN, -N (R) (CHR) nCF3, -N (R) (CHR) (CHR) n-OR, ...
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99115557 | 1999-08-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5180625A1 true CO5180625A1 (en) | 2002-07-30 |
Family
ID=8238742
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO00058410A CO5180625A1 (en) | 1999-08-06 | 2000-08-03 | 1,2,4,5-TETRAHYDRO-BENZO [D] AZEPINAS |
Country Status (27)
Country | Link |
---|---|
US (1) | US6218385B1 (en) |
JP (1) | JP3260350B2 (en) |
KR (1) | KR100390116B1 (en) |
CN (1) | CN1146455C (en) |
AR (1) | AR025035A1 (en) |
AT (1) | ATE254614T1 (en) |
AU (1) | AU774485B2 (en) |
BR (1) | BR0003375A (en) |
CA (1) | CA2314798A1 (en) |
CO (1) | CO5180625A1 (en) |
DE (1) | DE60006618T2 (en) |
ES (1) | ES2209728T3 (en) |
HR (1) | HRP20000520A2 (en) |
HU (1) | HUP0003112A3 (en) |
ID (1) | ID26743A (en) |
IL (1) | IL137688A0 (en) |
MA (1) | MA26748A1 (en) |
NO (1) | NO20003966L (en) |
NZ (1) | NZ506096A (en) |
PE (1) | PE20010467A1 (en) |
PL (1) | PL341890A1 (en) |
RU (1) | RU2240317C2 (en) |
SG (1) | SG93251A1 (en) |
TR (1) | TR200002298A2 (en) |
UY (1) | UY26276A1 (en) |
YU (1) | YU49700A (en) |
ZA (1) | ZA200003927B (en) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1260226C (en) * | 2000-12-22 | 2006-06-21 | 弗·哈夫曼-拉罗切有限公司 | Tetrahydro-(benzo or thieno)-azepine-pyrazine and triazine derivatives as mGluR1 antagonists |
US6953787B2 (en) | 2002-04-12 | 2005-10-11 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulators |
KR100897642B1 (en) * | 2002-12-20 | 2009-05-14 | 글락소 그룹 리미티드 | Benzazepine Derivatives for the Treatment of Neurological Disorders |
NZ578503A (en) * | 2003-06-17 | 2011-02-25 | Arena Pharm Inc | Benzazepine derivatives useful for the treatment of 5HT2C receptor associated diseases |
EP1636191A2 (en) | 2003-06-17 | 2006-03-22 | Arena Pharmaceuticals, Inc. | Benzazepine derivatives useful for the treatment of 5ht2c receptor associated diseases |
WO2005042490A1 (en) * | 2003-10-22 | 2005-05-12 | Arena Pharmaceuticals, Inc. | Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases |
US20080009478A1 (en) * | 2003-10-22 | 2008-01-10 | Arena Pharmaceuticals, Inc. | Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2c Receptor Associated Diseases |
CN102321023A (en) | 2004-12-21 | 2012-01-18 | 艾尼纳制药公司 | (R)-and 8-chloro-1-methyl-2,3,4, the crystal formation of 5-tetrahydrochysene-1H-3-benzazepine hydrochloride |
SI1833473T1 (en) * | 2004-12-23 | 2010-01-29 | Arena Pharm Inc | 5ht2c receptor modulator compositions and methods of use |
WO2007025177A2 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
EP2258357A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
US7985756B2 (en) | 2005-10-21 | 2011-07-26 | Braincells Inc. | Modulation of neurogenesis by PDE inhibition |
WO2007053596A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
WO2007120517A2 (en) | 2006-04-03 | 2007-10-25 | Arena Pharmaceuticals, Inc. | Processes for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates related thereto |
JP2009536667A (en) | 2006-05-09 | 2009-10-15 | ブレインセルス,インコーポレイティド | 5HT receptor-mediated neurogenesis |
WO2007134136A2 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
EP1873527A1 (en) * | 2006-06-30 | 2008-01-02 | Schwarz Pharma Ag | Method for identifying CRMP modulators |
BRPI0716604A2 (en) | 2006-09-08 | 2013-04-09 | Braincells Inc | combinations containing a 4-acylaminopyridine derivative |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
AU2007325836B2 (en) | 2006-11-22 | 2011-07-21 | Clinical Research Associates, Llc | Methods of treating mental retardation, Down's syndrome, fragile X syndrome and autism |
EP2099743B1 (en) * | 2006-12-05 | 2014-08-27 | Arena Pharmaceuticals, Inc. | Processes for preparing (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates thereof |
TW200845978A (en) * | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
EP2288585A1 (en) | 2008-03-04 | 2011-03-02 | Arena Pharmaceuticals, Inc. | Processes for the preparation of intermediates related to the 5-ht2c agonist (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine |
US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
WO2010148207A2 (en) | 2009-06-18 | 2010-12-23 | Arena Pharmaceuticals, Inc. | Processes for the preparation of 5-ht2c receptor agonists |
WO2011109398A2 (en) | 2010-03-02 | 2011-09-09 | President And Fellows Of Harvard College | Methods and compositions for treatment of angelman syndrome and autism spectrum disorders |
WO2011150380A1 (en) | 2010-05-28 | 2011-12-01 | Xenoport, Inc. | Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders |
KR20130112848A (en) | 2010-06-02 | 2013-10-14 | 아레나 파마슈티칼스, 인크. | Processes for the preparation of 5-ht2c receptor agonists |
WO2012009646A1 (en) | 2010-07-15 | 2012-01-19 | Xenoport, Inc. | Methods of treating fragile x syndrome, down's syndrome, autism and related disorders |
EP2611427B1 (en) | 2010-09-01 | 2018-10-17 | Arena Pharmaceuticals, Inc. | Modified-release dosage forms of 5-ht2c agonists useful for weight management |
EP2611782A1 (en) | 2010-09-01 | 2013-07-10 | Arena Pharmaceuticals, Inc. | Salts of lorcaserin with optically active acids |
US9365521B2 (en) | 2010-09-01 | 2016-06-14 | Arena Pharmaceuticals, Inc. | Non-hygroscopic salts of 5-HT2C agonists |
US8999970B2 (en) | 2010-09-01 | 2015-04-07 | Arena Pharmaceuticals, Inc. | Administration of an anti-obesity compound to individuals with renal impairment |
CA2886875A1 (en) | 2012-10-09 | 2014-04-17 | Arena Pharmaceuticals, Inc. | Method of weight management |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4206210A (en) * | 1977-01-19 | 1980-06-03 | Smithkline Corporation | Alkylthio-7,8-dihdroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines having dopaminergic activity |
KR930702292A (en) * | 1990-11-06 | 1993-09-08 | 알렌 제이. 스피겔 | Quinazolin derivatives for enhancing tumor therapeutic activity |
US5241065A (en) * | 1992-02-25 | 1993-08-31 | Schering Corporation | 2,3,4,5-tetrahydro-1h-3-benzazepines having anti-psychotic activity |
-
2000
- 2000-07-27 ES ES00116091T patent/ES2209728T3/en not_active Expired - Lifetime
- 2000-07-27 AT AT00116091T patent/ATE254614T1/en not_active IP Right Cessation
- 2000-07-27 DE DE60006618T patent/DE60006618T2/en not_active Expired - Fee Related
- 2000-08-01 MA MA26033A patent/MA26748A1/en unknown
- 2000-08-01 NZ NZ506096A patent/NZ506096A/en unknown
- 2000-08-01 CA CA002314798A patent/CA2314798A1/en not_active Abandoned
- 2000-08-01 US US09/630,702 patent/US6218385B1/en not_active Expired - Fee Related
- 2000-08-02 AU AU48979/00A patent/AU774485B2/en not_active Ceased
- 2000-08-02 PE PE2000000768A patent/PE20010467A1/en not_active Application Discontinuation
- 2000-08-02 HR HR20000520A patent/HRP20000520A2/en not_active Application Discontinuation
- 2000-08-02 ZA ZA200003927A patent/ZA200003927B/en unknown
- 2000-08-02 ID IDP20000655A patent/ID26743A/en unknown
- 2000-08-02 SG SG200004344A patent/SG93251A1/en unknown
- 2000-08-03 CO CO00058410A patent/CO5180625A1/en not_active Application Discontinuation
- 2000-08-03 IL IL13768800A patent/IL137688A0/en unknown
- 2000-08-04 JP JP2000236848A patent/JP3260350B2/en not_active Expired - Fee Related
- 2000-08-04 RU RU2000120522/04A patent/RU2240317C2/en not_active IP Right Cessation
- 2000-08-04 CN CNB001225235A patent/CN1146455C/en not_active Expired - Fee Related
- 2000-08-04 HU HU0003112A patent/HUP0003112A3/en unknown
- 2000-08-04 TR TR2000/02298A patent/TR200002298A2/en unknown
- 2000-08-04 NO NO20003966A patent/NO20003966L/en not_active Application Discontinuation
- 2000-08-04 KR KR10-2000-0045324A patent/KR100390116B1/en not_active IP Right Cessation
- 2000-08-04 AR ARP000104022A patent/AR025035A1/en not_active Application Discontinuation
- 2000-08-04 UY UY26276A patent/UY26276A1/en not_active Application Discontinuation
- 2000-08-07 PL PL00341890A patent/PL341890A1/en unknown
- 2000-08-07 BR BR0003375-8A patent/BR0003375A/en not_active Application Discontinuation
- 2000-08-07 YU YU49700A patent/YU49700A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5180625A1 (en) | 1,2,4,5-TETRAHYDRO-BENZO [D] AZEPINAS | |
PE20021002A1 (en) | CONDENSED HETEROCYCLIC COMPOUNDS | |
LU91196I2 (en) | Picoxystrobin and its pharmaceutically acceptable derivatives (ACANTO). | |
EA200601639A1 (en) | ISOXAZOLINE-SUBSTITUTED DERIVATIVE BENZAMIDE AND PESTICIDE | |
MY140012A (en) | Heterocylic substituted phenyl methanones | |
CO5090835A1 (en) | BICYCLE [2.2.1] HEPTANS AND RELATED COMPOUNDS | |
DK645688D0 (en) | 3- (4- (1-SUBSTITUTED 4-PIPERAZINYL) BUTYL) -4-THIAZOLIDINONES, THEIR PREPARATION AND USE | |
AR039226A2 (en) | USEFUL COMPOUNDS AS PREPARATION INTERMEDIARIES AND PROCEDURES | |
CO5140087A1 (en) | DERIVATIVES OF 3-PHENYL-PYRIDINE YOUR SYNTHESIS PROCEDURE AND MEDICINES CONTAINING THEM | |
AR061372A1 (en) | AMINO-IMIDAZOLES AND ITS USES AS MEDICINES FOR THE TREATMENT OF ALZHEIMER EVIL, DEMENTIA AND NEURODEGENERATION | |
PE20001088A1 (en) | TETRAHIDROBENZAZEPINE DERIVATIVE COMPOUNDS | |
CO5160347A1 (en) | CARBAMIC ACID DERIVATIVES | |
ES2086326T3 (en) | METHOD FOR INTENSIFYING CHEMILUMINESCENCE. | |
NZ511584A (en) | Benzoxazole substituted piperazine and piperidine derivatives useful for treating central nervous disorders, depression and anxiety | |
CO5650231A2 (en) | DERIVATIVES OF 1- (ALQUILAMINOALQUIL-PIRROLIDIN- / PIPERIDINIL) -2,2-DIFENYLACETAMIDE AS ANTAGONISTS OF THE MUSCARINIC RECEIVER, ITS SYNTHESIS PROCEDURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
CO5590896A2 (en) | CHEMICAL COMPOUNDS | |
AR072118A1 (en) | PIRROLIDINE DERIVATIVES AS AN NG2 RECEIVER ANTAGONISTS | |
RU95122287A (en) | NIPECOTINIC ACID DERIVATIVES AS SUBSTANCES THAT IMPEDE THE DISTRIBUTION | |
AR064137A1 (en) | DERIVATIVES OF INDOL-2-IL-CARBONIL-PIPERIDINA-BENZOIMIDAZOLONA AND INDOL-2-IL-CARBONIL-PIPERIDINA-BENZOXAZOLONA, VASOPRESINE V1A RECEIVER ANTAGONISTS, METHOD OF OBTAINING, COMPOSITIONS AND FARMACEUVENOS TO PREVENT US TREAT CORONARY, DEPRESSIVE AND OTHER ENFE DISORDERS | |
AR032379A1 (en) | DERIVATIVES OF 1,2,4,5-TETRAHYDRO-BENZO (D) AZEPINA-PIRAZINA AND TRIAZINA AND DERIVATIVES OF 1,2,4,5-TETRAHYDRO-TIENO (D) AZEPINA-PIRAZINA AND TRIAZINA | |
ATE146479T1 (en) | MODIFIED OLIGODEOXYRIBONUCLEOTIDES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | |
PE20001482A1 (en) | 2-AMINOPYRIDINES CONTAINING CONDENSED RING-TYPE SUBSTITUTES | |
PE20020687A1 (en) | IMIDAZOLES AND THIAZOLS SUBSTITUTED AS INHIBITORS OF FARNESIL TRANSFERASE | |
AR043964A1 (en) | DERIVATIVES OF 4- (2-PHENYLSULPHANYL-PHENYL) 1,2,3,6-TETRAHYDROPIRIDINE AS ANHIBITORS OF SEROTONIN RECAPTATION | |
AR064135A1 (en) | DERIVATIVES OF ESPIRO -PIPERIDINA |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application lapsed |